R&D Strategy

AKLRD’s focus is primarily inflammatory diseases, particularly those related to dysregulation of the innate immune system.

AKLRD identifies secondary metabolites of plant origin with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development.

AKLRD’s innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.

This has resulted in our lead candidate AKL4 [APPA], a patented investigational oral medicine showing great promise in the treatment of inflammatory conditions including osteoarthritis, a highly prevalent and devastating disease with limited treatment options and no cure.

Currently in Phase I, early assessment of disease modification will be made at Phase II.

We welcome enquiries from potential investors and partners in this development and commercialisation process.